)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Tenaya Therapeutics
Tenaya Therapeutics (TNYA) investor relations material
Tenaya Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Clinical pipeline centers on TN-201 and TN-401 gene therapies in Phase 1b/2 trials; TN-301 is planned for a company-sponsored Phase 2 trial in H2 2027.
Q3 net loss was $18.9M, or $0.08 per share; cash of $66.8M is expected to fund planned operations into Q4 2027.
Near-term milestones include TN-201 and TN-401 clinical data and regulatory feedback on pivotal-trial planning, expected by year-end 2026.
Financial highlights
Q3 collaboration revenue was $1.7M versus $3.0M in Q3 2025; 9M revenue was $14.9M versus $15.4M.
Q3 operating expenses were $21.3M versus $20.9M YoY; operating loss was $19.6M versus $20.9M, and net loss was $18.9M versus $20.3M.
9M operating expenses rose 20% to $86.8M, including $22.5M impairment and $1.4M lease-termination loss; net loss increased 16% to $81.6M from $70.4M.
9M R&D declined 14% to $46.3M and G&A declined 12% to $16.5M; Q3 R&D was $14.9M versus $15.4M, while G&A was $5.6M in both periods.
Outlook and guidance
TN-201 longer-term MyPEAK-1 data and pivotal-planning regulatory update, and additional TN-401 RIDGE-1 data and regulatory update, are expected by year-end 2026.
TN-301 study-enabling work is underway; at least one company-sponsored Phase 2 trial is planned for H2 2027, subject to enabling toxicology work.
R&D spending over the next 12 months will depend on trial data, regulatory alignment on pivotal plans for TN-201 and TN-401, and TN-301 Phase 2 plans.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Tenaya Therapeutics
- Stockholders to vote on a board-discretionary 1-for-10 to 1-for-25 reverse split.TNYA
Proxy filing - Stockholders face a discretionary reverse split proposal amid Nasdaq bid-price concerns.TNYAProxy filing
- A discretionary 1-for-10 to 1-for-25 reverse split targets Nasdaq bid-price compliance.TNYAProxy filing
- Durable clinical improvements and strong market interest drive pivotal planning for gene therapy assets.TNYAH.C. Wainwright 28th Annual Global Investment Conference
- Q4 will bring pivotal regulatory and clinical updates across all major heart disease programs.TNYACanaccord Genuity's 46th Annual Growth Conference
- Q2 2026 net loss rose to $43.4M on impairment; cash runway extends through Q3 2027.TNYAQ2 2026
- Durable efficacy and safety in gene therapy programs drive pivotal trial plans for 2026.TNYAJefferies Global Healthcare Conference 2026
- TN-201 gene therapy produced durable cardiac and symptomatic improvements in MYBPC3-HCM patients.TNYAStudy result
- Gene therapy for MYBPC3-HCM shows safety, efficacy, and protocol-related FDA hold; timelines intact.TNYAStatus Update
Next Tenaya Therapeutics earnings date
Q4 202610 Mar, 2027
Tenaya Therapeutics
Next Tenaya Therapeutics earnings date
Q4 202610 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Tenaya Therapeutics Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for heart disease. The company's approach involves multiple therapeutic modalities, including gene therapy, cellular regeneration, and precision medicine, to address both rare genetic and prevalent forms of cardiovascular disease. Tenaya's research aims to target the underlying causes of heart disease, offering potential treatments for conditions that currently have limited therapeutic options. The company is headquartered in South San Francisco, California, and its shares are listed on the Nasdaq.